Use of composition of 5'-monophosphate nucleotide or sodium salt form thereof in preparation of drug and / or functional food for preventing and treating cardiovascular diseases
By using a combination of 5'-monophosphate nucleotides or their sodium salt forms, vascular endothelial cell function is promoted, solving the problem of the lack of cardiovascular disease prevention and treatment in the prior art, and achieving significant cell repair and atherosclerosis prevention effects.
Patent Information
- Application Number
- PCT/CN2025/123869
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2025-09-25
- Publication Date
- 2026-11-12
AI Technical Summary
There is a lack of effective nucleotide compositions in the prior art for the prevention and treatment of cardiovascular diseases, especially for the prevention and treatment of atherosclerosis by improving vascular endothelial cell function.
Combinations using 5'-monophosphate nucleotides or their sodium salts can improve cell proliferation and repair by promoting the expression of specific genes in vascular endothelial cells and inhibiting VCAM-1 protein, thereby preventing and treating cardiovascular diseases.
It significantly promotes DNA replication and division in damaged cells, inhibits VCAM-1 protein expression, reduces visceral fat levels and leptin levels, improves blood flow, reduces cardiac burden, and prevents and treats cardiovascular diseases such as atherosclerosis.
Smart Images

Figure CN2025123869_12112026_PF_FP_ABST
Abstract
Description
Application of compositions of 5'-monophosphate nucleotides or their sodium salts in the preparation of pharmaceuticals and / or functional foods for the prevention and treatment of cardiovascular diseases. Technical Field
[0001] This invention relates to the field of pharmaceutical technology, and more specifically, to the use of a composition of a 5'-monophosphate nucleotide or its sodium salt in the preparation of medicaments and / or functional foods for the prevention and treatment of cardiovascular diseases. Background Technology
[0002] From July 2021 to June 2022, the "China Residents' Cardiovascular and Cerebrovascular Event Monitoring" project found that the crude incidence rate of cardiovascular disease among Chinese residents aged ≥18 years was 600.9 / 100,000, including acute myocardial infarction, angina pectoris requiring coronary intervention and / or bypass surgery, stroke, and sudden cardiac death. The age-standardized incidence rate was 411.8 / 100,000, and it is accelerating at an increasingly rapid pace. The development of cardiovascular disease is a long-term process; early intervention can significantly reduce the risk of developing the disease.
[0003] Vascular endothelial cells are a single layer of cells forming the inner wall of blood vessels. They are highly specialized cells with multiple functions, including regulating vascular tone, controlling blood flow, maintaining the integrity of the blood vessel wall, and participating in blood clotting. However, with age, the metabolic rate slows down, making it difficult for cells to replicate and proliferate, resulting in damage that is difficult to repair, eventually leading to diseases such as arteriosclerosis.
[0004] Modified low-density lipoprotein (LDL) enters the subendothelial layer through the gaps between endothelial cells. The increased expression of adhesion factors (such as VCAM-1) on the surface of dysfunctional endothelial cells makes it easier for monocytes in the blood circulation to adhere to the vascular endothelial surface. Then, under the action of the chemokines released by the monocytes, the monocytes migrate to the subendothelial layer. These monocytes differentiate into macrophages under the action of colony-stimulating factors, and then engulf the modified LDL in the subendothelial layer, becoming foam cells. At this time, lipid streaks are formed in the early stage of atherosclerosis.
[0005] Nucleotides, composed of pentose sugars, bases, and phosphate groups, are the basic building blocks of nucleic acids, essential substances for somatic cells, and regulators of the metabolism of various nutrients in the body. Recent studies have found that exogenous nucleotides possess various physiological activities, including immunomodulation, antioxidant activity, and anti-aging effects. In a prior application, the applicant discovered the application of nucleotides and their compositions in improving mitochondrial function in H2O2-induced senescent fibroblasts.
[0006] However, no research has been reported on the use of nucleotides and their combinations for the prevention and treatment of cardiovascular diseases. Summary of the Invention
[0007] The purpose of this invention is to overcome the above-mentioned defects in the prior art and provide an application of a composition of 5'-monophosphate nucleotide or its sodium salt in the preparation of drugs and / or functional foods for the prevention and treatment of cardiovascular diseases. This invention provides a new application of 5'-monophosphate nucleotide, offering a new option for the prevention and treatment of cardiovascular diseases.
[0008] To achieve the above objectives, the technical solution of the present invention is as follows:
[0009] The use of compositions of 5'-monophosphate nucleotides or their sodium salts in the preparation of pharmaceuticals and / or functional foods for the prevention and / or treatment of cardiovascular diseases.
[0010] Optionally, the composition comprises 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate, and hypoxanthine nucleotide.
[0011] Optionally, the mass ratios of the nucleotides in the composition converted to CMP, AMP, UMP, GMP, and IMP acid forms are as follows: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, and IMP is 0, or greater than 0 but not higher than 2.5%.
[0012] Optionally, the mass ratios of the various nucleotides in the composition converted to CMP, AMP, UMP, GMP, and IMP acid forms are as follows: CMP: 15-45%, AMP: 15-25%, UMP: 15-30%, GMP: 15-35%, and IMP is 0, or greater than 0 but not higher than 2.5%.
[0013] Optionally, the dosage form of the drug includes at least one of powder, tablet, soft or hard capsule, and oral liquid.
[0014] Optionally, the functional food includes at least one of powder, tablet, soft capsule, hard capsule, dairy product, baked product, and liquid beverage.
[0015] Optionally, the composition is produced by enzymatic degradation of ribonucleic acid as a raw material, with a purity of over 99%.
[0016] Optionally, the drug and / or functional food promotes the expression of pola2, DNA2, FEN1, PLK1, CCNB2, CCNA2, CCNB1, CDC25A, HSP90AA1, AURKA, and SGO1 genes in vascular endothelial cells, thereby promoting DNA replication, maturation, and division at the site of injury, achieving cell proliferation, and repairing the damage.
[0017] Optionally, the drug and / or functional food prevent and / or treat atherosclerosis by inhibiting the expression of VCAM-1 protein.
[0018] Optionally, the drug and / or functional food may reduce the incidence of cardiovascular disease by lowering visceral fat levels, improving blood flow, and reducing the burden on the heart.
[0019] Optionally, the drug and / or functional food may prevent and / or treat atherosclerosis by lowering leptin levels in the body, improving endocrine metabolism and blood lipid levels.
[0020] Optionally, the medicine and / or functional food may help prevent heart disease by lowering heart rate and enhancing cardiac stability.
[0021] Optionally, the cardiovascular disease includes at least one of hypertension, coronary heart disease, stroke, heart failure, and aortic infarction.
[0022] Optionally, the composition may further comprise a formulation of one or more optional nutritional supplements, including folic acid, earthworm protein, lovastatin, and other pharmaceutically acceptable excipients.
[0023] Implementing the embodiments of the present invention will have the following beneficial effects:
[0024] (1) The composition of 5'-monophosphate nucleotide or its sodium salt provided by the present invention can significantly upregulate the expression of genes such as pola2, DNA2, FEN1, PLK1, CCNB2, CCNA2, CCNB1, CDC25A, HSP90AA1, AURKA, and SGO1 in vascular endothelial cells, effectively promote DNA replication in damaged cells, accelerate cell maturation and division, achieve cell proliferation, and thus repair damage.
[0025] (2) The composition of 5'-monophosphate nucleotide or its sodium salt form provided by the present invention can significantly inhibit the expression of VCAM-1 protein, play a preventive and therapeutic role in atherosclerosis, and thus prevent and / or treat cardiovascular diseases caused by atherosclerosis.
[0026] (3) The 5'-monophosphate nucleotide or its sodium salt composition provided by the present invention has a significant effect on the prevention and treatment of cardiovascular diseases through the synergistic effect of two pathways and the raw materials are highly safe. It can also be used as a functional food or medicine.
[0027] (4) Human trials have shown that the combination of 5'-monophosphate nucleotides or their sodium salts provided by the present invention can significantly reduce multiple indicators such as visceral fat level (VFG), leptin and heart rate, thereby preventing and / or treating cardiovascular diseases caused by atherosclerosis. Attached Figure Description
[0028] Figure 1 shows the effect of the 5'-monophosphate nucleotide or its sodium salt composition of the present invention on the transcriptional level of senescent endothelial cells (A is a volcano plot of differentially expressed genes between the blank control group and the model control group; B is a volcano plot of differentially expressed genes between the nucleotide mixture group and the model control group; C is the enrichment of upregulated genes in the KEGG pathway between the nucleotide mixture group and the model control group; red represents upregulation, green represents downregulation, and blue represents no significant difference).
[0029] Figure 2 shows the effect of the composition of the present invention, either 5'-monophosphate or its sodium salt form, on the cell cycle regulation system of senescent endothelial cells.
[0030] Figure 3 shows the effect of the composition of the present invention, either 5'-monophosphate or its sodium salt form, on the percentage of aortic plaque in mice.
[0031] Figure 4 shows the effect of the composition of the present invention, specifically the 5'-monophosphate nucleotide or its sodium salt form, on the expression of VCAM-1 protein in the mouse aorta. Detailed Implementation
[0032] The present invention will be further described below with reference to specific embodiments, but this does not limit the present invention in any way.
[0033] The five 5'-monophosphate nucleotides in the 5'-monophosphate nucleotide compositions used in the following examples are 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate, and hypoxanthine nucleotide.
[0034] Production process: Ribonucleic acid (RNA) with a purity of 90% is produced through heat denaturation → enzymatic hydrolysis with nuclease P1 → ultrafiltration → adsorption onto anion exchange resin → stepwise elution → nanofiltration desalting → membrane concentration → carbon powder decolorization → crystallization → drying. The above five types of 5'-monophosphate nucleotides are tested separately, and those that pass the tests are used.
[0035] Example 1
[0036] The 5'-monophosphate nucleotide composition used in this embodiment includes 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, and disodium 5'-uridine monophosphate. The effective percentage contents of each nucleotide, calculated as CMP, AMP, UMP, and GMP, are as follows: CMP 43%, AMP 17%, UMP 22%, and GMP 18%.
[0037] The above four 5'-monophosphate nucleotides or their sodium salts were tested separately, and after passing the tests, they were passed through a 60-mesh sieve for later use. The required amount of each monophosphate nucleotide sample was weighed according to the above proportions, and the mixture was mixed for a time of not less than 40 minutes. The resulting mixed sample was stored at room temperature.
[0038] Example 2
[0039] The 5'-monophosphate nucleotide composition used in this embodiment includes 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, and disodium 5'-uridine monophosphate. The effective percentage contents of each nucleotide, calculated as CMP, AMP, UMP, and GMP, are as follows: CMP 18%, AMP 25%, UMP 24%, and GMP 33%.
[0040] The above four 5'-monophosphate nucleotides or their sodium salts were tested separately, and after passing the tests, they were passed through a 60-mesh sieve for later use. The required amount of each monophosphate nucleotide sample was weighed according to the above proportions, and the mixture was mixed for a time of not less than 40 minutes. The resulting mixed sample was stored at room temperature.
[0041] Example 3
[0042] The 5'-monophosphate nucleotide composition used in this embodiment includes 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate, and hypoxanthine nucleotide. The effective percentage contents of each nucleotide, calculated as CMP, AMP, UMP, GMP, and IMP, are as follows: CMP 28%, AMP 24%, UMP 28%, GMP 19%, and IMP 1%.
[0043] The above five 5'-monophosphate nucleotides or their sodium salts were tested separately, and after passing the tests, they were passed through a 60-mesh sieve for later use. The required amount of each monophosphate nucleotide sample was weighed according to the above proportions, and the mixture was mixed for a time of not less than 40 minutes. The resulting mixed sample was stored at room temperature.
[0044] Example 4
[0045] Compared with Example 1, this embodiment also includes earthworm protein, lovastatin, folic acid and filler.
[0046] Specifically as follows:
[0047] The composition used in this embodiment is formulated in the following proportions: 25% of the 5'-monophosphate nucleotide composition prepared in Example 1, 20% of earthworm protein, 0.24% of lovastatin, 0.01% of folic acid, with the remainder being fillers.
[0048] After the raw materials pass the inspection, they are mixed for 30 minutes using an HZD-1000 mixer. The content of the active ingredients in the finely mixed powder is then determined. The finely mixed powder is then loaded into a CFM-1200 fully automatic capsule filling machine to fill the capsules, and the filling amount is adjusted to be between 0.30g±8% per capsule.
[0049] Example 5
[0050] This embodiment examines the effects of the 5'-monophosphate nucleotide composition of Example 1 on the cell cycle regulation system and cell maturation and division of senescent endothelial cells.
[0051] Human umbilical vein endothelial cells (HUVECs) used in the experiment were purchased from Zhejiang Meisen Cell Technology Co., Ltd. Cells were cultured in DMEM high-glucose medium containing 1% penicillin / streptomycin and 10% fetal bovine serum at 37°C under saturated humidity conditions with 5% CO2. Three groups were formed: a normal control group cultured in complete medium; cells from the aging model group and experimental groups, after adhesion, were cultured in complete medium containing 200 μmol / L hydrogen peroxide for 4 h; after discarding the hydrogen peroxide-containing medium, the experimental group was added to complete medium containing 100 μmol / L of the 5'-monophosphate nucleotide composition prepared in Example 1; and the model group was incubated in complete medium for 24 h. Cells were collected by trypsin digestion, washed twice with PBS, flash-frozen in liquid nitrogen, and stored at -80°C in the dark. Routine mRNA-seq analysis was performed on cells from the blank control group, aging model control group, and the group supplemented with the 5'-monophosphate nucleotide composition.
[0052] All materials, reagents, and instruments used in the experiment were commercially available. Transcriptome data were analyzed only for genes with FPKM>1, and genes with FDR-p<0.05 were considered differentially expressed. GO functional enrichment analysis and KEGG pathway enrichment analysis of differentially expressed gene sets were performed using Cluster Profiler v3.4.4. Transcriptome data are shown in Table 1 and Figure 1.
[0053] Table 1. Effects of 5'-monophosphate nucleotide compositions on transcriptional levels in senescent endothelial cells.
[0054] Result 1: Effect of 5'-monophosphate nucleotide composition on transcriptional levels in senescent endothelial cells
[0055] Transcriptomic analysis was performed on cell samples from the normal control group, model control group, and the group supplemented with mixed nucleotides. As shown in Figure 1, compared with the normal control group, 146 genes were upregulated and 80 genes were downregulated in the senescent model group (Figure 1A). Compared with the senescent model group, 236 genes were upregulated and 405 genes were downregulated in the group supplemented with the nucleotide composition (Figure 1B). KEGG pathway enrichment results of differentially expressed gene sets showed that the nucleotide composition supplement significantly upregulated DNA replication, cell cycle progression, oocyte maturation, and division in senescent endothelial cells (Figure 1C).
[0056] Result 2: Effects of 5'-monophosphate nucleotide composition on the cell cycle regulation system of senescent endothelial cells
[0057] As shown in Table 1, transcriptomic data revealed that supplementation with the 5'-monophosphate nucleotide composition significantly upregulated the CCNA2 gene in senescent endothelial cells. This gene encodes the G1 phase protein Cyclin A, which initiates DNA replication. Supplementation with the 5'-monophosphate nucleotide composition also significantly upregulated the expression of the POLα2, DNA2, and FEN1 genes in senescent endothelial cells. These genes encode DNA polymerase, DNA replication helicase / nuclease, and endonuclease, respectively, indicating that supplementation with the 5'-monophosphate nucleotide composition can effectively promote DNA replication in the S phase of the cell cycle. Furthermore, supplementation with the 5'-monophosphate nucleotide composition significantly upregulated the expression of the CCNB2 gene in senescent endothelial cells. This gene encodes the M phase protein Cyclin B, which promotes the transition from G2 to M phase. Finally, supplementation with the 5'-monophosphate nucleotide composition significantly upregulated the expression of the CDC25A and PLK1 genes in senescent endothelial cells. The CDC25A gene encodes the cell cycle phosphatase CDC25, and PLK1 encodes a serine-threonine protein kinase. The serine-threonine protein kinase can dephosphorylate and activate CDC25, which in turn can dephosphorylate and activate Cyclin A and Cyclin B. These results indicate that the 5'-monophosphate nucleotide combination promotes DNA replication and cell cycle progression by upregulating the expression of multiple genes in the cell cycle regulatory system (Figure 2).
[0058] Result 3: Effects of 5'-monophosphate nucleotide composition on maturation and division of senescent endothelial cells
[0059] As shown in Table 1, transcriptomic data showed that supplementing with the 5'-monophosphate nucleotide composition significantly promoted cell maturation and division in senescent endothelial cells by upregulating the expression of genes such as PLK1, HSP90AA1, CCNB2, CCNA2, CCNB1, CDC25A, AURKA, and SGO1.
[0060] Example 6
[0061] Fifty SPF-grade LDLR- / - mice were purchased commercially. The SPF-grade LDLR- / - mice were 8 weeks old and female.
[0062] Mice were randomly divided into five groups of 10 each: Group A, Group B, Group C, Group D, and Group E. Group A was fed a normal diet, Group B was fed a high-fat diet, and Groups E were fed a high-fat diet (0.3 g / kg / day) containing the 5'-monophosphate nucleotide composition prepared in Examples 1-3. All mice in each group had free access to food and water.
[0063] Mice were euthanized after 14 weeks of feeding for subsequent molecular and pathological experiments. The aorta (including the aortic arch and thoracic aorta) was removed from the mice. After obtaining the fresh aortic specimen, excess peripheral fat and tissue were removed under a stereomicroscope.
[0064] One portion of the mice was fixed overnight in 4% paraformaldehyde. The next day, it was removed, washed with PBS, longitudinally split, and placed in PBS. Before Oil Red O staining, it was placed in 60% isopropanol for 12 seconds, then stained in 0.3% Oil Red O for 5 minutes. It was then rinsed in 60% isopropanol until the vessel wall turned white, rinsed with PBS, and photographed. The plaque deposition in the aorta was analyzed using ImageJ software. The plaque area ratio was calculated as the ratio of the plaque deposition area to the total aortic area (referred to as plaque percentage). The average value of each group of mice was taken. The results are shown in Figure 3. The diets containing the 5'-monophosphate nucleotide combination in groups C, D, and E can inhibit atherosclerosis to a certain extent, thereby preventing cardiovascular diseases.
[0065] Another portion of the preparation involved 10% tissue homogenate for use in the detection kit. The VCAM-1 detection kit was provided by Miltiscience Co., Ltd. (Hangzhou, China) and was sourced from Miltiscience Co., Ltd. The results, as shown in Figure 4, indicate that compared to the high-fat diet group (group B), the expression of VCAM-1 protein in the arteries of group C, fed with the 5'-monophosphate nucleotide composition, was significantly inhibited.
[0066] Example 7
[0067] This embodiment employs a randomized, double-blind trial design to evaluate the efficacy of the 5'-monophosphate nucleotide or its sodium salt composition prepared in Example 1 in patients with cardiovascular disease.
[0068] 1. Test Methods
[0069] 1.1. Preparation of Capsules
[0070] The capsules used in this trial will be provided by Zhenao Group Co., Ltd. The placebo control group capsules and the nucleotide intervention group capsules contain only excipients and different doses of nucleotides, differing only in nucleotide content. Each capsule contains 0.4g and is taken 4 capsules daily. Each capsule in the placebo control group contains 0.4g of excipients, and each capsule in the nucleotide intervention group contains 0.1g of excipients + 0.3g of nucleotides.
[0071] 1.2. Experimental Design and Participants
[0072] This trial is an exploratory, 19-week, single-center, double-blind, randomized, placebo-controlled study that recruits community residents through advertising for a comprehensive health assessment, including clinical health check-ups, questionnaires, physical function assessments, and anthropometry. Eligibility was determined according to the following criteria: Inclusion criteria: (1) Age between 60 and 70 years; (2) No serious physical or mental illness; (3) No prior use of nucleotide-related supplements or health foods; (4) Ability to follow the study protocol and provide informed consent. Exclusion criteria: (1) Diagnosed diseases such as autoimmune diseases, serious cardiovascular and cerebrovascular diseases, complications of major organs such as the liver and kidneys, or other serious diseases such as malignant tumors, pancreatic diseases, and mental illnesses; (2) Abnormal screening laboratory test values or other laboratory test results, excluding the researcher's judgment; (3) Severe visual or hearing impairments that affect communication; (4) Participation in other clinical trials within the past 6 months; (5) Use of foods or drugs related to the tested function. All participants provided informed written consent in accordance with the Declaration of Helsinki prior to their recruitment into the study.
[0073] 1.3. Sample size and randomization
[0074] The sample size for this study was determined according to the "Technical Specifications for Inspection and Evaluation of Health Foods" issued by the National Health Commission of China, which recommends at least 50 participants per group in human intervention trials. Participants were randomly assigned to the intervention group and the control group in a 1:1 ratio. To estimate a 20% loss to follow-up rate, a total of 301 participants were included in the study.
[0075] Participants are randomly assigned to groups using computer-generated random numbers. The protocol is known only to the study designers, who are not involved in data collection or analysis. The randomization code is sealed and will only be unblinded in the event of a serious adverse event.
[0076] 1.3. Intervention and Blinding
[0077] The intervention was administered in capsule form to ensure consistency in appearance, taste, and formulation between the placebo (pure starch excipient) and the intervention (a combination of 5'-monophosphate nucleotides or their sodium salts from Example 1 plus starch excipient) to avoid any suspicion among participants. The placebo capsules were designed similarly to the intervention capsules. Each capsule in the intervention group contained 0.1 g of starch excipient and 0.3 g of the 5'-monophosphate nucleotides or their sodium salts from Example 1, while each placebo capsule contained 0.4 g of starch excipient. Participants were instructed to take four capsules daily while maintaining a regular lifestyle and diet. A double-blind design ensured that participants and researchers, including investigators, clinicians, data collectors, and follow-up coordinators, remained unaware of group assignments. The capsules were packaged in opaque bottles labeled only with the participant identifier. The blinding procedure was explained in detail to participants during the informed consent process.
[0078] 1.4. Participation in the Experiment
[0079] A total of 301 older adults who were willing to participate and signed informed consent forms were recruited. After screening, 123 participants were ultimately selected as eligible to participate. The most common reason for exclusion was non-compliance with inclusion criteria (n=175). One participant in the nucleotide group withdrew before the intervention began. The intervention lasted for 19 weeks. During the follow-up period, except for one participant in the nucleotide group who withdrew after one week of intervention due to a traffic accident, the remaining 121 participants completed the trial. Therefore, a total of 121 participants who completed the intervention were ultimately included in the statistical analysis. There were no significant differences between the two groups in any baseline characteristics. The mean age of the participants was 65.65 years (standard deviation 2.59), of whom 82 (67.21%) were female.
[0080] 1.5. Data Collection
[0081] In this study, data were collected at baseline (T0), mid-term (T1), and terminal (T2). Clinical examinations and biological sample collection (blood, etc.) were performed at the physical examination hospital.
[0082] Bioelectrical impedance analysis (BIA) was used to measure visceral fat grade (VFG) and other body composition.
[0083] 1.6. Statistical Analysis
[0084] This study employed intention-to-treat (ITT) principles in its data analysis, and no imputation was performed on missing data in the baseline data. The Shapiro-Wilk test was used to assess data normality, and the Levene test to assess homogeneity of variance. Based on the variable distribution characteristics, the independent samples t-test (for normally distributed data) or the Mann-Whitney U test (for non-normally distributed data) was used to compare pre-intervention, post-intervention, and changes between groups. Effect sizes were calculated using Cohen's d-value, derived from the difference between the two group means, where d = 0.2 represents a small effect size, d = 0.5 a moderate effect size, and d = 0.8 a large effect size.
[0085] This study employed generalized estimating equations (GEE) to analyze all outcome measures, specifying an exchangeable work-related structure. Data from all baselines and endpoints were used. Independent variables in Model 1 included group, time, group-time interaction terms, baseline dependent variable (a continuous variable), age, and sex. We also developed Model 2, further adjusting for dietary nucleotide intake. Similarly, Model 3 further adjusted for dietary purine intake. The intervention effect was determined by the coefficients of the interaction terms in the models and their 95% confidence intervals (CIs).
[0086] 2. Results
[0087] 2.1 Effects on visceral fat grade
[0088] This part of the study aims to comprehensively evaluate the effects of combinations of 5'-monophosphate nucleotides or their sodium salt forms on visceral fat grades.
[0089] As shown in Table 2, there was no significant difference in visceral fat grade between the two groups of elderly individuals at baseline (P>0.05), indicating that the baseline conditions of the two groups were comparable. Analysis of the differences between groups in the changes before and after the intervention (T2-T0) revealed that the change in NTs decreased in the NTs group while it increased in the C group. The change in NTs was smaller in the NTs group than in the C group (NTs: -0.05±0.96, C: 0.36±0.84), and the difference was statistically significant (P=0.01). The effect size between groups was small (d=-0.46).
[0090] As shown in Table 3, the visceral fat grade of the NTs group was significantly lower than that of the C group (β = -0.40, 95% CI: -0.73 to -0.08). This significant reduction was statistically significant and consistent across all models (P = 0.01).
[0091] The results of this study show that the supplementation in Example 1 had a certain impact on body composition in the elderly population, manifested as a significant reduction in visceral fat grade, which has important biological significance: the reduction of visceral fat has potential benefits for the prevention of metabolic syndrome, cardiovascular disease and chronic inflammation-related diseases.
[0092] Table 2 Analysis of the Influence of Visceral Fat Grade
[0093] *T0 represents the baseline time point, T1 represents the mid-intervention time point (10 weeks), and T2 represents the intervention endpoint time point (19 weeks). T1-T0 represents the change from baseline to mid-intervention, T2-T0 represents the change from baseline to intervention endpoint, and T2-T1 represents the change from mid-intervention to intervention endpoint.
[0094] *The p-value is obtained through a t-test, and Cohen's d is used to quantify the effect size.
[0095] *When the P value is less than 0.01, it is represented as "<0.01".
[0096] Table 3 shows the test results of the generalized estimation equation model for visceral fat grades.
[0097] *T0 represents the baseline time point, and T2 represents the intervention endpoint time point (19 weeks).
[0098] *The p-value is based on a generalized estimation equation. The model considers the interaction between groups and time, as well as covariates. The assessment time points include baseline and intervention endpoint.
[0099] Model 1 adjusted covariates: baseline value, age, gender;
[0100] Model 2 adjusted covariates: baseline values, age, sex, and changes in dietary nucleotide intake;
[0101] Model 3 adjusted covariates: baseline values, age, sex, and changes in dietary purine intake.
[0102] *When the P value is less than 0.01, it is represented as "<0.01".
[0103] 2.2 Effects on heart rate changes in the elderly
[0104] This part of the study aims to comprehensively evaluate the effects of combinations of 5'-monophosphate nucleotides or their sodium salt forms on heart rate variability in older adults.
[0105] As shown in Table 4, there were no significant differences in heart rate parameters between the two groups of elderly individuals at baseline (P>0.05), indicating that the baseline conditions of the two groups were comparable. Analysis of the differences between groups in the changes before and after the intervention (T2-T0) revealed that heart rate decreased in both groups. The change in heart rate in the NTs group was greater than that in the C group (NTs: -1.09±9.15, C: -0.72±8.79), but the difference was not statistically significant (P=0.83), and the effect size between groups was small (d=-0.04).
[0106] Table 5 shows the test results of the generalized estimation equation model. Compared with group C, the heart rate of the NTs group (β = -0.21, 95% CI: -3.42 to 3.00) showed a decreasing trend, but it was not statistically significant and was consistent in all models (P > 0.05).
[0107] The results of this study showed that the heart rate reduction was more significant in the NTs group compared to the C group, suggesting that nucleotide intervention improves the efficiency of the subjects' hearts, enabling them to maintain normal blood circulation at a slower rate. This phenomenon is usually associated with enhanced cardiac function or improved cardiac adaptation.
[0108] Table 4 Analysis of the impact on heart rate
[0109] *T0 represents the baseline time point, T1 represents the mid-intervention time point (10 weeks), and T2 represents the intervention endpoint time point (19 weeks). T1-T0 represents the change from baseline to mid-intervention, T2-T0 represents the change from baseline to intervention endpoint, and T2-T1 represents the change from mid-intervention to intervention endpoint. *P-values are obtained through t-tests, and Cohen's d's law is used to quantify the effect size.
[0110] *When the P value is less than 0.01, it is represented as "<0.01".
[0111] Table 5 shows the test results of the generalized estimation equation model for heart rate.
[0112] *T0 represents the baseline time point, and T2 represents the intervention endpoint time point (19 weeks).
[0113] *The p-value is based on a generalized estimation equation. The model considers the interaction between groups and time, as well as covariates. The assessment time points include baseline and intervention endpoint.
[0114] Model 1 adjusted covariates: baseline value, age, gender;
[0115] Model 2 adjusted covariates: baseline values, age, sex, and changes in dietary nucleotide intake;
[0116] Model 3 adjusted covariates: baseline values, age, sex, and changes in dietary purine intake.
[0117] *When the P value is less than 0.01, it is represented as "<0.01".
[0118] 2.3 Effects on leptin levels in the elderly
[0119] This part of the study aims to comprehensively evaluate the effects of exogenous nucleotides on leptin in older adults.
[0120] As shown in Table 6, there was no significant difference in leptin levels between the two groups of elderly individuals at baseline (P>0.05), indicating that the baseline conditions of the two groups were comparable. Analysis of the differences between groups in the changes before and after the intervention (T2-T0) revealed that leptin levels decreased in both groups. The change in leptin levels in the NTs group was smaller than that in the C group (NTs: -461.14±914.23, C: -60.71±1017.81), and the difference was statistically significant (P=0.03). The effect size between groups was moderate (d=-0.41).
[0121] Table 7 shows the results of the generalized estimation equation model tests. Compared with group C, the NTs group showed a significant decrease in leptin levels (β = -395.44, 95% CI: -741.26 to -49.62), a statistically significant difference consistent across all models (P = 0.03). These results indicate that leptin is secreted by adipose tissue, and its content is directly proportional to the size of the adipose tissue. The significantly lower leptin levels in the NTs group compared to group C suggest that the NTs group exhibits improved metabolic regulation and lipid control.
[0122] Table 6 Analysis of the effect on leptin
[0123] *T0 represents the baseline time point, T1 represents the mid-intervention time point (10 weeks), and T2 represents the intervention endpoint time point (19 weeks). T1-T0 represents the change from baseline to mid-intervention, T2-T0 represents the change from baseline to intervention endpoint, and T2-T1 represents the change from mid-intervention to intervention endpoint.
[0124] * The p-value is obtained through a t-test, and Cohen's d ...
[0125] Table 7 shows the test results of the generalized estimation equation model for leptin.
[0126] *T0 represents the baseline time point, and T2 represents the intervention endpoint time point (19 weeks).
[0127] *The p-value is based on a generalized estimation equation. The model considers the interaction between groups and time, as well as covariates. The assessment time points include baseline and intervention endpoint.
[0128] Model 1 adjusted covariates: baseline value, age, gender;
[0129] Model 2 adjusted covariates: baseline values, age, sex, and changes in dietary nucleotide intake;
[0130] Model 3 adjusted covariates: baseline values, age, sex, and changes in dietary purine intake.
[0131] *When the P value is less than 0.01, it is represented as "<0.01".
[0132] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.
Claims
The use of compositions of 1,5'-monophosphate nucleotides or their sodium salts in the preparation of pharmaceuticals and / or functional foods for the prevention and treatment of cardiovascular diseases.
2. The application according to claim 1, characterized in that, The composition comprises 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate, and hypoxanthine nucleotide.
3. The application according to claim 2, characterized in that, The mass ratios of the nucleotides in the composition converted to CMP, AMP, UMP, GMP, and IMP acid forms are as follows: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, and IMP is 0, or greater than 0 but not higher than 2.5%.
4. The application according to claim 3, characterized in that, The mass ratios of the various nucleotides in the composition, converted to CMP, AMP, UMP, GMP, and IMP acid forms, are as follows: CMP: 15-45%, AMP: 15-25%, UMP: 15-30%, GMP: 15-35%, and IMP is 0, or greater than 0 but not higher than 2.5%.
5. The application according to claim 1, characterized in that, The dosage form of the drug includes at least one of powder, tablet, soft or hard capsule, and oral liquid. The functional foods include at least one of the following: powders, tablets, soft capsules, hard capsules, dairy products, baked goods, and liquid beverages; The composition is produced by enzymatic degradation of ribonucleic acid as raw material, with a purity of over 99%.
6. The application according to claim 1, characterized in that, The composition may also comprise a formulation of one or more optional nutritional supplements, including folic acid, earthworm protein, lovastatin, and other pharmaceutically acceptable excipients.
7. The application according to claim 1, characterized in that, The drug and / or functional food promote the expression of pola2, DNA2, FEN1, PLK1, CCNB2, CCNA2, CCNB1, CDC25A, HSP90AA1, AURKA, and SGO1 genes in vascular endothelial cells, thereby promoting DNA replication, maturation, and division at the site of injury, achieving cell proliferation, and repairing damage.
8. The application according to claim 1, characterized in that, The drugs and / or functional foods prevent and / or treat atherosclerosis by inhibiting the expression of VCAM-1 protein.
9. The application according to claim 1, characterized in that, The aforementioned drugs and / or functional foods reduce the incidence of cardiovascular disease by lowering visceral fat levels, improving blood flow, and reducing the burden on the heart. The drugs and / or functional foods prevent and / or treat atherosclerosis by lowering the body's leptin levels, improving endocrine metabolism and blood lipid levels; The aforementioned drugs and / or functional foods help prevent heart disease by lowering heart rate and enhancing cardiac stability.
10. The application according to claim 1, characterized in that, The cardiovascular diseases mentioned include at least one of hypertension, coronary heart disease, stroke, heart failure, and aortic infarction.
